About this Journal Submit a Manuscript Table of Contents
Journal of Oncology
Volume 2012 (2012), Article ID 521215, 11 pages
http://dx.doi.org/10.1155/2012/521215
Review Article

Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck

Winship Cancer Institute, Emory University, 1365 Clifton Road Northeast Atlanta, GA 30322, USA

Received 12 January 2012; Accepted 19 April 2012

Academic Editor: Bruno Vincenzi

Copyright © 2012 Walid Shaib et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Kalyankrishna and J. R. Grandis, “Epidermal growth factor receptor biology in head and neck cancer,” Journal of Clinical Oncology, vol. 24, no. 17, pp. 2666–2672, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Grandis and D. J. Tweardy, “Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer,” Cancer Research, vol. 53, no. 15, pp. 3579–3584, 1993. View at Scopus
  4. J. Rubin Grandis, M. F. Melhem, E. L. Barnes, and D. J. Tweardy, “Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck,” Cancer, vol. 78, no. 6, pp. 1284–1292, 1996.
  5. M. Maurizi, G. Almadori, G. Ferrandina et al., “Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma,” British Journal of Cancer, vol. 74, no. 8, pp. 1253–1257, 1996. View at Scopus
  6. G. B. van den Broek, V. B. Wreesmann, M. W. M. Van Den Brekel, C. R. N. Rasch, A. J. M. Balm, and P. H. Rao, “Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma,” Clinical Cancer Research, vol. 13, no. 15, pp. 4386–4391, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. E. W. Cohen, “Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 24, no. 17, pp. 2659–2665, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. N. F. Saba, F. R. Khuri, and D. M. Shin, “Targeting the epidermal growth factor receptor: trials in head and neck and lung cancer,” Oncology, vol. 20, no. 2, pp. 153–161, 2006. View at Scopus
  9. R. S. Herbst, “Review of epidermal growth factor receptor biology,” International Journal of Radiation Oncology, Biology, Physics, vol. 59, no. 2, supplement, pp. 21–26, 2004.
  10. R. L. Davies, V. A. Grosse, R. Kucherlapati, and M. Bothwell, “Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 7, pp. 4188–4192, 1980. View at Scopus
  11. J. Downward, P. Parker, and M. D. Waterfield, “Autophosphorylation sites on the epidermal growth factor receptor,” Nature, vol. 311, no. 5985, pp. 483–485, 1984. View at Scopus
  12. K. Oda, Y. Matsuoka, A. Funahashi, and H. Kitano, “A comprehensive pathway map of epidermal growth factor receptor signaling,” Molecular Systems Biology, vol. 1, Article ID 2005.0010, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Zimmermann, A. Zouhair, D. Azria, and M. Ozsahin, “The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications,” Radiation Oncology, vol. 1, no. 1, article 11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. B. Ryerson, E. S. Peters, S. S. Coughlin et al., “Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998–2003,” Cancer, vol. 113, no. 10, pp. 2901–2909, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. L. Gillison, W. M. Koch, R. B. Capone et al., “Evidence for a causal association between human papillomavirus and a subset of head and neck cancers,” Journal of the National Cancer Institute, vol. 92, no. 9, pp. 709–720, 2000. View at Scopus
  16. A. K. Chaturvedi, E. A. Engels, R. M. Pfeiffer, et al., “Human papillomavirus and rising oropharyngeal cancer incidence in the United States,” Journal of Clinical Oncology, vol. 29, no. 32, pp. 4294–4301, 2011. View at Publisher · View at Google Scholar
  17. R. Herrero, X. Castellsagué, M. Pawlita et al., “Human papillomavirus and oral cancer: the international agency for research on cancer multicenter study,” Journal of the National Cancer Institute, vol. 95, no. 23, pp. 1772–1783, 2003. View at Scopus
  18. G. D'Souza, A. R. Kreimer, R. Viscidi et al., “Case-control study of human papillomavirus and oropharyngeal cancer,” The New England Journal of Medicine, vol. 356, no. 19, pp. 1944–1956, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Kamb, N. A. Gruis, J. Weaver-Feldhaus et al., “A cell cycle regulator potentially involved in genesis of many tumor types,” Science, vol. 264, no. 5157, pp. 436–440, 1994. View at Scopus
  20. T. Nobori, K. Miura, D. J. Wu, A. Lois, K. Takabayashi, and D. A. Carson, “Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers,” Nature, vol. 368, no. 6473, pp. 753–756, 1994. View at Publisher · View at Google Scholar · View at Scopus
  21. H. C. Hafkamp, E. J. M. Speel, A. Haesevoets et al., “A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8,” International Journal of Cancer, vol. 107, no. 3, pp. 394–400, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Reimers, H. U. Kasper, S. J. Weissenborn et al., “Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer,” International Journal of Cancer, vol. 120, no. 8, pp. 1731–1738, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Crusius, E. Auvinen, B. Steuer, H. Gaissert, and A. Alonso, “The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT,” Experimental Cell Research, vol. 241, no. 1, pp. 76–83, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Kumar, K. G. Cordell, J. S. Lee et al., “EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3128–3137, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. H. Kim, B. S. Koo, S. Kang et al., “HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation,” International Journal of Cancer, vol. 120, no. 7, pp. 1418–1425, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Rischin, R. J. Young, R. Fisher et al., “Prognostic significance of p16INK4Aand human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial,” Journal of Clinical Oncology, vol. 28, no. 27, pp. 4142–4148, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” The New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Aboud-Pirak, E. Hurwitz, F. Bellot, J. Schlessinger, and M. Sela, “Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 10, pp. 3778–3781, 1989. View at Scopus
  29. E. Aboud-Pirak, E. Hurwitz, M. E. Pirak, F. Bellot, J. Schlessinger, and M. Sela, “Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice,” Journal of the National Cancer Institute, vol. 80, no. 20, pp. 1605–1611, 1988. View at Scopus
  30. V. A. Pollack, D. M. Savage, D. A. Baker et al., “Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 291, no. 2, pp. 739–748, 1999. View at Scopus
  31. K. K. Ang, B. A. Berkey, X. Tu et al., “Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma,” Cancer Research, vol. 62, no. 24, pp. 7350–7356, 2002. View at Scopus
  32. J. Mendelsohn and J. Baselga, “Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2787–2799, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Dittmann, C. Mayer, B. Fehrenbacher et al., “Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase,” Journal of Biological Chemistry, vol. 280, no. 35, pp. 31182–31189, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Baselga, D. Pfister, M. R. Cooper et al., “Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin,” Journal of Clinical Oncology, vol. 18, no. 4, pp. 904–914, 2000. View at Scopus
  35. F. Robert, M. P. Ezekiel, S. A. Spencer et al., “Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer,” Journal of Clinical Oncology, vol. 19, no. 13, pp. 3234–3243, 2001. View at Scopus
  36. J. Bourhis, F. Rivera, R. Mesia et al., “Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2866–2872, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. P. M. Fracasso, H. Burris, M. A. Arquette et al., “A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing,” Clinical Cancer Research, vol. 13, no. 3, pp. 986–993, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. D. M. Shin, N. J. Donato, R. Perez-Soler et al., “Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer,” Clinical Cancer Research, vol. 7, no. 5, pp. 1204–1213, 2001. View at Scopus
  39. J. B. Vermorken, J. Trigo, R. Hitt et al., “Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2171–2177, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Hitt, A. Irigoyen, H. Cortes-Funes, et al., “Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck,” Annals of Oncology, vol. 23, no. 4, pp. 1016–1022, 2012. View at Scopus
  41. K. Ang, Q. Zhang, R. H. Wheeler, et al., “A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome,” Journal of Clinical Oncology, vol. 28, supplement, abstract 5507, p. 15s, 2010.
  42. R. S. Herbst, M. Arquette, D. M. Shin et al., “Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5578–5587, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Rozzi, C. Nardoni, M. Corona, M. R. Restuccia, T. Falbo, and G. Lanzetta, “Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study,” Journal of Chemotherapy, vol. 22, no. 6, pp. 419–423, 2010. View at Scopus
  44. J. Baselga, J. M. Trigo, J. Bourhis et al., “Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5568–5577, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Burtness, M. A. Goldwasser, W. Flood, et al., “Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8646–8654, 2005.
  46. J. B. Vermorken, R. Mesia, F. Rivera et al., “Platinum-based chemotherapy plus cetuximab in head and neck cancer,” The New England Journal of Medicine, vol. 359, no. 11, pp. 1116–1127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Mesía, F. Rivera, A. Kawecki et al., “Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck,” Annals of Oncology, vol. 21, no. 10, pp. 1967–1973, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Licitra, R. Mesia, F. Rivera et al., “Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study,” Annals of Oncology, vol. 22, no. 5, pp. 1078–1087, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. J. B. Vermorken, J. Stohlmacher, I. Davidenko, et al., “Primary efficacy and safety results of SPECTRUM, a phase III trial in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) receiving chemotherapy with or without panitumumab,” Annals of Oncology, vol. 21, 2010.
  50. L. J. Wirth, A. M. Allen, M. R. Posner et al., “Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck,” Annals of Oncology, vol. 21, no. 2, pp. 342–347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. J. B. Vermorken and P. Specenier, “Optimal treatment for recurrent/metastatic head and neck cancer,” Annals of Oncology, vol. 21, supplement 7, pp. vii252–vii261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. J. P. Machiels, S. Subramanian, A. Ruzsa et al., “Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 12, no. 4, pp. 333–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. J. S. Stewart, E. E. Cohen, and L. Licitra, “Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1864–1871, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Argiris, M. Ghebremichael, B. Burtness, R. S. Axelrod, R. C. Deconti, and A. A. Forastiere, “A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303),” Cancer, vol. 117, no. 15, pp. 3374–3382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Y. Seiwert, P. M. Clement, D. Cupissol et al., “BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: preliminary results of a randomized, open-label phase II study,” Journal of Clinical Oncology, vol. 28, p. 15s, 2010.
  56. L. L. Siu, D. Soulieres, E. X. Chen et al., “Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group study,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2178–2183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. E. E. Cohen, D. W. Davis, T. G. Karrison et al., “Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study,” The Lancet Oncology, vol. 10, no. 3, pp. 247–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. E. E. W. Cohen, F. Rosen, W. M. Stadler et al., “Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 1980–1987, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarvala, and L. L. Siu, “Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 77–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. G. M. Higa and J. Abraham, “Lapatinib in the treatment of breast cancer,” Expert Review of Anticancer Therapy, vol. 7, no. 9, pp. 1183–1192, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Yonesaka, K. Zejnullahu, I. Okamoto, et al., “Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab,” Science Translational Medicine, vol. 3, no. 99, Article ID 99ra86, 2011. View at Publisher · View at Google Scholar
  62. J. A. Engelman, K. Zejnullahu, T. Mitsudomi et al., “MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling,” Science, vol. 316, no. 5827, pp. 1039–1043, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. S. H. Bigner, P. A. Humphrey, A. J. Wong et al., “Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts,” Cancer Research, vol. 50, no. 24, pp. 8017–8022, 1990. View at Scopus
  64. S. E. Wheeler, S. Suzuki, S. M. Thomas et al., “Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation,” Oncogene, vol. 29, no. 37, pp. 5135–5145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. J. C. Sok, F. M. Coppelli, S. M. Thomas et al., “Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting,” Clinical Cancer Research, vol. 12, no. 17, pp. 5064–5073, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. M. J. Jameson, A. D. Beckler, L. E. Taniguchi, et al., “Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells,” Molecular Cancer Therapeutics, vol. 10, no. 11, pp. 2124–2134, 2011.
  67. E. A. Bohula, M. P. Playford, and V. M. Macaulay, “Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment,” Anti-Cancer Drugs, vol. 14, no. 9, pp. 669–682, 2003. View at Scopus